William Blair analyst Andrew Brackmann has maintained their bullish stance on VCYT stock, giving a Buy rating on May 5.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Veracyte’s strong performance and promising future prospects. The company’s first-quarter results demonstrated robust durability in its testing business, meeting revenue expectations and showcasing significant earnings potential with an AEBITDA increase that surpassed consensus estimates. This financial strength is further supported by the company’s ability to expand its AEBITDA margin substantially, indicating effective cost management strategies.
In addition to the solid core business performance, Brackmann notes the exciting growth opportunities within Veracyte’s pipeline. The company is on the cusp of launching several key products over the next 12 to 18 months, which are expected to drive further growth. Notably, the upcoming launch of Prosigna as a laboratory-developed test in the U.S. by mid-2026 represents a significant milestone. These developments, alongside confirmed timelines for other pipeline products, reinforce Brackmann’s positive outlook on Veracyte’s long-term potential, justifying his Buy rating.